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Purpose: To assess the clinical pattern, the histopathological findings, the response to treatments, the 
recurrence pattern and the prognosis of malignant lymphoma in the ocular adnexa.
Methods: This study was performed on 22 total eyes from 17 patients who were diagnosed with ocular 
adnexal malignant lymphoma. We retrospectively analyzed the medical records for patient information 
including the histological classification based on age, the gender of each patient, the symptoms and signs 
at the initial diagnosis, the presence of binocular invasion, the findings of the surgical biopsy, the clinical 
stage of each patient's tumor, and the treatment methods used and their effectiveness. The mean follow-up 
period was 24.8 months. 
Results: The mean age of patients studied was 46.8 years old. Six females and 11 males were included 
in the study. Fifteen cases consisting of 20 total eyes represented extranodal marginal zone B cell lymphoma 
of mucosa-associated lymphoid tissue (MALT). Five of seven patients (71.4%) whose lymphoma occurred 
within the conjunctiva relapsed after irradiation or chemotherapy, and four of the relapsed patients were 
salvaged with further therapy.
Conclusions: Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT) 
constituted 88.2% of all lymphomas involving the ocular adnexa. Lymphoma in the ocular adnexa responded 
well to conventional treatment, but the recurrence rate of lymphoma in the conjunctiva was significantly high.  
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Malignant lymphomas represent approximately 10% of 
orbital tumors.
1-4 In addition, 5-8% of extranodal lymphomas 
involve the orbit, and 1.3-2.0% of extranodal lymphomas 
appear as primary orbital tumors.
3,5 The incidence of primary 
orbital tumors has recently been on the rise due to environ-
mental and lifestyle changes as well as to advances in the 
histopathological diagnostic techniques using immunohisto-
chemical and molecular analysis.
1,3-5
After numerous controversies regarding the classification 
of malignant lymphoma, a new WHO classification was 
established founded on the 1994 REAL classification that 
was based on a variety of objective information such as the 
presence of various immune markers or the analysis of gene 
expression within each lymphoma, along with morphological 
and clinical findings from each case studied.
6,7 
Based on the histopathological analysis of the reported 
studies, the extranodal marginal zone B cell lymphoma of the 
mucosa-associated lymphoid tissue (MALT) is reported to 
account for 38-64% of ocular adnexal lymphomas.
5,8,9 In 
contrast to lymphomas of other organs, ocular adnexal 
lymphomas are low malignancy MALT lymphomas in most 
cases and have a relatively benign structure of the lymphoid 
follicle.
10
Treatment of extranodal marginal zone B cell lymphoma 
by surgical resection, radiation and chemotherapy is effective 
when compared with the efficacy of treating lymphomas from 
other cell types.
1,4,9,10-13 However, recurrence and metastasis 
have been reported in several cases and prognosis is poor in 
cases with systemic metastasis.
11,14,15 Hence, we assessed the 
clinical pattern, the histopathological findings, the response to 
various treatments, the recurrence pattern and the prognosis 
of patients with malignant lymphoma in the ocular adnexa. Korean  J  Ophthalmol  Vol.20,  No.1,  2006
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Materials and Methods
This study comprised 22 total eyes from 17 patients who 
were diagnosed with ocular adnexal malignant lymphoma and 
treated at the Dong-A University Hospital from October 1999 
to June 2004. We retrospectively analyzed the patients’ 
medical records including the histological classification based 
on patient age and gender; the symptoms and signs present 
at the initial diagnosis; the findings from the surgical 
biopsies; the presence of binocular invasion; the clinical 
stages based on the presence of systemic invasion; the 
treatment methods used and the effectiveness of those 
treatments. The mean duration follow-up period was 24.8 
months, with a range of 12 to 53 months.
A histological diagnosis was performed in all cases. To 
demonstrate the presence of monoclonal characteristics within 
the studied tumors, the expression of κ  and λ  immuno-
globulin light chains (using monoclonal antibodies diluted to 
1:300 and 1:000 respectively, Dako Corporation) was 
assessed by flow cytometry. The biopsy specimens were 
fixed in 10% formalin and embedded in paraffin. Hemato-
xylin-eosin staining was then performed. Immunohisto-
chemical testing was performed using the peroxidase- 
antiperoxiadase (PAP) technique with antibodies against IgG, 
IgM, CD3 (1:50, Dako Corporation, Santa Barbara, CA, 
USA), CD5 (1:100), CD10 (1:100), CD20 (1:100), CD23 
(1:100), and CD45RO (1:50).
Each of the studied lymphomas was histopathologically 
reclassified according to the WHO classification published in 
1997.
6-7 The clinical staging was determined according to the 
Ann Arbor staging system.
16 In the case of invasion to both 
eyes, the consensus on the disease stage has not yet been 
reached. In this study, however, bilateral orbital involvement 
without any other lesions outside the orbit was classified as 
stage I EE according to other investigator's criteria.
17-19
The treatment modalities were determined according to the 
Ann Arbor criteria. In cases where lesions were limited to 
the orbit, radiation therapy of 3,000-4,000 cGy was primarily 
administered after surgical resection for a complete cure. For 
patients with monocular blindness or with small lymphocytic 
lymphoma (B cells), chemotherapy using the CHOP regimen 
(cyclophosphamide, vincristine, doxirubicin, and prednisone) 
was administered. In the cases with systemic invasion, 
radiation therapy and chemotherapy were administered 
simultaneously for symptomatic purposes.
The response after treatment was evaluated based on the 
Response Criteria of non-Hodgkin's lymphoma as recom-
mended by the National Cancer Institute (NCI) in 1998. All 
patients were evaluated with a full physical examination, a 
biopsy of the suspected conjunctival lesion and periodical 
orbital CT. In cases with an absence of tumors in the lymph 
nodes and at the primary site as assessed by clinical 
examination, biopsy and CT analyses were deemed as 
complete remission (CR); the reduction of tumors in the 
primary site by over 75% was deemed as uncompleted 
remission (CRu); the reduction of tumors in the primary site 
by over 50% was deemed as partial remission (PR); and the 
detection of new lesions or an increase of the tumor size was 
deemed as relapse or progression.
20
During patient follow-up, the complications during or after 
treatment were assessed by questioning the patients, by 
taking patient physicals and by performing slit-lamp exami-
nations. 
Results
1. Clinical pattern
The age of patients ranged from 28 years to 89 years and 
the mean age was 46.8 years old. Six females and 11 males 
were included in the study. The major symptoms listed in the 
order of decreasing frequency were proptosis, lid swelling, a 
painless palpable mass and blurred vision (Table 1). Proptosis 
was detected in 8 patients with orbital tumors, and a painless 
palpable mass was noted in 5 of the patients. Seven patients 
with tumors in the conjunctiva complained of symptoms like 
keratoconjunctivitis. In a patient with decreased visual acuity, 
the tumor had invaded the vicinity of the optic nerve as 
visualized on the orbital CT. 
The location of each lymphoma was limited to the 
conjunctiva in 10 eyes from 6 patients and limited to the orbit 
in 10 eyes from 9 patients. Lymphoma was simultaneously 
detected in the conjunctiva and in the orbit at the time of the 
diagnosis in one patient. The tumor was located in the orbit, 
the bone marrow and the submandibular gland in this patient.
Except for one patient with the simultaneous invasion to the 
conjunctiva and the orbit, lymphomas were detected in both 
eyes in 4 of 6 patients with tumors in their conjunctiva. 
According to the Ann Arbor clinical stages at the time of 
diagnosis of 16 patients with ocular adnexa-limited 
lymphoma, 11 patients whose lesions were limited to the 
monocular adnexa displayed stage IE, and 5 patients that 
displayed invasion to the binocular adnexa were classified as 
stage IEE. One patient that displayed stage IV had 
metastasized to the bone marrow and the submandibular 
gland.
2. Histopathological findings
The histopathological classification was done according to 
the WHO classification. Twenty total eyes from 15 patients 
of extranodal marginal zone B cell lymphoma of mucosa- 
associated lymphoid tissue (MALT) were examined. In 
patients 14 and 15, who had mainly extranodal marginal zone 
B cell lymphoma of mucosa-associated lymphoid tissue 
(MALT), the focal transformation to large B cell lymphoma 
was detected. One patient (1 eye) was diagnosed with diffuse 
large B cell lymphoma that was positive for CD20 and 
CD45. Another patient (1 eye) with small lymphocytic B cell 
lymphoma was positive for IgM and CD20. JM  Woo,  et  al,  OCULAR  ADNEXAL  LYMPHOMA
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Patient
No. Sex Age Laterality Presenting 
symptom Location Clinical 
staging WHO  classification*
1 M 89 left palpable  mass  orbit IE Diffuse  large  B  cell  lymphoma
2 M 44 right proptosis orbit IE Marginal  zone  B  cell  lymphoma
3 F 43 both lid  swelling conjunctiva IEE Marginal  zone  B  cell  lymphoma
4 M 41 left lid  swelling conjunctiva,  orbit IE Marginal  zone  B  cell  lymphoma
5 M 58 right proptosis orbit IE Marginal  zone  B  cell  lymphoma
6 M 44 both lid  swelling conjunctiva IEE Marginal  zone  B  cell  lymphoma
7 F 31 left lid  swelling conjunctiva IE Small  lymphocytic  B  cell  lymphoma 
8 M 47 right proptosis orbit IE Marginal  zone  B  cell  lymphoma
9 F 59 right lid  swelling conjunctiva IE Marginal  zone  B  cell  lymphoma
10 M 68 left proptosis orbit IE Marginal  zone  B  cell  lymphoma
11 M 37 right lid  swelling orbit IE Marginal  zone  B  cell  lymphoma
12 F 42 both lid  swelling orbit IEE Marginal  zone  B  cell  lymphoma
13 M 48 left proptosis orbit IE Marginal  zone  B  cell  lymphoma
14 M 30 both lid  swelling conjunctiva IEE Marginal  zone  B  cell  lymphoma  with  focal 
transformation  to  large  B-cell  lymphoma
15 M 40 both lid  swelling conjunctiva IEE Marginal  zone  B  cell  lymphoma  with  focal 
transformation  to  large  B-cell  lymphoma
16 F 43 right proptosis orbit IE Marginal  zone  B  cell  lymphoma
17 F 28 right visual  disturbance orbit, 
submaxillar  LN
†, 
bone  marrow
IV Marginal  zone  B  cell  lymphoma
*WHO:  World  Health  Organization, 
†LN:  lymph  node.
Table 1. Summary  of  clinical  and  histopathologic  findings
Patient
No. Treatment Effect  on  ocular 
adnexa
Response  criteria
of  NHL*
F/U
α
(mo) S t a t u s  a t  l a s t  F / U
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
RT
†
CT
‡(CHOP
β)
RT
RT
RT
RT
CT  (CHOP)
RT
CT  (CHOP)
RT
RT
RT
RT
RT
RT
RT
RT  &  CT
Orbital  mass  disappeared
Orbital  mass  disappeared
Relapsed  orbital  mass
Relapsed  on  other  eye
Orbital  mass  disappeared
Relapsed  orbital  mass 
Relapsed  orbital  mass 
Orbital  mass  disappeared
Relapsed  orbital  mass
residual  mass
residual  mass
residual  mass
residual  mass
Orbital  mass  disappeared
Orbital  mass  disappeared
Orbital  mass  disappeared
Improved  visual  acuity
CR
§
CR
Relapse
Relapse
CR
Relapse
Relapse
CR
Relapse
CRu
∏
CRu
CRu
CRu
CR
CR
CR
Progression
14
37
18
49
12
37
30
34
44
13
12
12
12
24
15
5
15
No  evidence  of  ds
# 
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s  
N o  e v i d e n c e  o f  d s  
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
Died  of  LC
γ
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
N o  e v i d e n c e  o f  d s
Metastasis
*NHL:  Non-Hodgkin's  lymphoma, 
†RT:  radiation  therapy, 
‡CT:  chemotherapy, 
§CR:  complete  remission, 
∏CRu:  uncompleted  remission, 
#ds:  disease, 
αF/U:  follow-up, 
βCHOP:  cyclophosphamide＋vincristin＋doxirubicin＋prednisone, 
γLC:  liver  cirrhosis.
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Patient 
No. Primary  location Tx* 
(cGy  or  regimen)
Relapse
site
Relapse  period 
(mo) 2nd  Tx
Response  criteria
of  NHL
†
3 conjunctiva  (both) RT
‡(3600) conjunctiva  (left) 5 RT(2000)
  &  CT  (CHOP)
CR
∏
4 conjunctiva,  orbit  (left) RT  (3060) conjunctiva  (right) 28 RT  (3000) CR
6 conjunctiva  (both) RT  (3420) conjunctiva  (right) 22 RT  (2800) CR
7c o n j u n c t i v a   ( l e f t ) C T
§(CHOP) conjunctiva  (left) 15 RT  (3000) CR
9 conjunctiva  (right) CT  (CHOP) conjunctiva  (right) 44
*Tx:  treatment, 
†NHL:  Non-Hodgkin's  lymphoma, 
‡RT:  radiation  therapy, 
§CT:  chemotherapy, 
∏CR:  complete  remission.
Table 3. Summary  of  relapsed  patients
Complications Eyes Percentage  (%)
lid  flush
conjunctival  injection
dry  eye
keratitis
skin  discoloration
periocular  edema
cataract
retinal  complications
21
20
17
10
 5
 3
 2
 0
95.4
90.9
77.2
45.4
22.7
13.6
9
0
Table 4. Complications  of  radiation  therapy 3. Treatment efficacy and outcome 
Of the 17 patients, 16 patients (totaling 21 eyes) with 
disease limited to the orbit were primarily treated by biopsy 
and partial resection followed by 20 cycles of radiation 
therapy (3,000-4,000 cGy) or chemotherapy (CHOP: cyclo-
phosphamide＋vincristine＋doxorubicin＋prednisone). 
According to the response criteria for non-Hodgkin's 
lymphoma recommended by the National Cancer Institute 
(NCI), 11 patients showed complete remission and 4 patients 
showed uncompleted remission. Although a patient with 
systemic metastasis was simultaneously treated by radiation 
and chemotherapy, he died 15 months after the treatment. 
In 4 patients with primary tumors in the orbit, residual tumors 
were detected by CT after the completion of radiation 
therapy. These residual tumors were reduced in size by over 
75%. During the 12-13 month follow-up period, new tumors 
or metastasis were not detected. Thus, these cases were 
classified as uncompleted remissions (Table 2).
Tumors relapsed after treatment in 5 patients and the overall 
recurrence rate was 31.3%. The lymphomas relapsed in 2 of 
3 patients who were treated with chemotherapy for their 
primary treatment. Relapse was detected in 2 of 5 patients 
with binocular invasion. Of the 7 patients with tumors in 
their conjunctiva, the recurrence rate was 71.4% and the 
tumor recurred in 5 patients during follow-up. Additional 
radiation therapy or chemotherapy was administered to 
patients with recurring tumors, except in one case where the 
patient died of liver cirrhosis 44 months after the relapse. 
After the fifth month of radiation therapy, a tumor relapsed 
on left conjunctiva of patient number 3 who had tumors on 
both conjunctiva. It was treated completely with additional 
radiation (2,000 cGy) and chemotherapy (CHOP regimen). 
For patient number 4 who had a tumor in the monocular 
conjunctiva and in the orbit, the tumor relapsed in the 
opposite conjunctiva at the 28th month and regressed with 
additional radiation therapy (3,000 cGy). For patient number 
6 with tumors in both conjunctiva, radiation therapy was 
given and the tumor recurred on the right conjunctiva at the 
22nd month. It was then treated with radiation therapy (2,800 
cGy) and remitted completely. Patient number 7, who had 
small lymphocytic lymphoma in the monocular conjunctiva, 
was treated with chemotherapy (CHOP regimen) as the 
primary treatment. The tumor relapsed at the 15th month and 
was treated with radiation therapy (3,000 cGy), which was 
followed by complete regression (Table 3).
A patient who had systemic invasion at the time of 
diagnosis, despite treatment with radiation therapy and 
chemotherapy, died 15 months after the treatment. However, 
the reduced exophthamos and improved visual acuity helped 
to improve his quality of life.
After radiation therapy, lid flushing and conjunctival 
injection were detected in most patients. Such complications 
were temporary and were relieved with the administration of 
steroid eye drops. Additional complications were dry eyes 
(77.2%), keratitis (45.4%), skin discoloration (22.7%), 
periocular edema (12%), and cataracts (9%), listed in the 
order of decreasing frequency. Retinal complications were 
not detected during follow-up (Table 4).
Discussion
The incidence of malignant lymphoma in the ocular 
adnexa was previously reported as being approximately 10% 
of total orbital tumors.
1,3,4 The incidence has recently been on 
the rise. In eastern Asia, the incidence of malignant lymphoma 
has been reported to be 18.4-28.0%.
2,21,22
In regard to the ratio of males and females with the 
disease, the incidence of non-Hodgkin's lymphoma is known 
to be higher in males than in females.
23,24 Similarly, lymphoma 
of the ocular adnexa has been shown to occur more 
frequently in males.
11,14,19 In our study, 11 cases were in JM  Woo,  et  al,  OCULAR  ADNEXAL  LYMPHOMA
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males and 6 cases in females, with a higher incidence in 
males.
The mean age of patients included in the study was 46.8 
years, with ages ranging from 28 to 89 years. Two of 17 
patients (11.7%) were under 30 years old and 5 patients were 
under 40 years (29.4%). Previous studies generally reported 
a higher age of incidence for MALT lymphoma in the range 
of 59-65 years.
4,5,8,9,22 Although MALT lymphoma is typically 
a disease of the elderly, this study showed an incidence of 
MALT lymphoma in patients of a much younger age, which 
contrasts with the mean age of the patients with MALT 
lymphoma reported in the literature. Recent studies of Korean 
patients with lymphoma in the ocular adnexa have reported 
that the mean age of patients with MALT lymphoma was 
44-48 years.
25-28 Hence, in regard to MALT lymphoma of the 
ocular adnexa, this disease occurs at a younger age in Korea 
than in western countries or Japan.
The clinical characteristics of lymphoma of the ocular 
adnexa are diverse according to the location of tumors, and 
we observed multiple symptoms including conjunctival 
injection, lid swelling, proptosis, painless palpable mass, 
ptosis, foreign body sensation, and blurred vision. In 7 
patients with lymphoma in the conjunctiva, lid swelling and 
conjunctival injection were detected. These patients were 
previously treated for conjunctivitis a long time prior to 
diagnosis. In 4 of 7 patients with lymphoma in the 
conjunctiva, including a patient whose lymphoma involved 
both the conjunctiva and orbit, lymphoma was detected in 
both eyes. Study guidelines required that both eyes be 
examined at the first examination and during the follow-up 
observation period. The cases misdiagnosed as having an 
atypical infection such as chlamydia have been reported 
because of continuous conjunctival injection and lid 
swelling.
29,30 If the eye condition showed the symptoms of 
conjunctivitis and it did not improve in response to conven-
tional treatments, a confirmation biopsy was considered 
necessary.
In the present study, extranodal marginal zone B cell 
lymphoma of mucosa-associated lymphoid tissue (MALT) 
constituted 88.2% of all lymphomas involving the ocular 
adnexa. This rate is much higher than the 50-79.5% reported 
in the previous studies of patients originating from Japan or 
western countries.
3-5,9 Recently, Cho et al. and Lee et al. each 
reported incidences of 89.7% and 86%, respectively, of 
MALT-type ocular adnexal lymphoma in Koreans.
27,28 These 
results may reveal the higher incidence of MALT lymphoma 
and the lower incidence of other types of lymphoma in 
Koreans. 
The clinical staging was determined according to the Ann 
Arbor staging system.16 However, in the case of invasion to 
both eyes, the consensus on the disease stage has not yet 
been reached. Kim et al. and Stafford et al. classified 
multiple lesions in the same site of the diaphragm as stage 
II.
11,17 However, because bilateral orbital lymphoma has 
subsequently been shown to be able to respond completely 
to treatment with only radiation therapy, thus giving it a 
prognosis identical to a unilateral tumor, it is classified as 
stage I.
10,18,19 In a similar fashion, bilateral ocular adnexal 
lymphoma was classified as stage IEE in this study.
Lymphomas in the ocular adnexa respond well to radiation 
therapy or chemotherapy.
10-14,18,19 According to studies reported 
up until presently, MALT lymphoma in the conjunctiva also 
responds well to radiation therapy or chemotherapy.
1,11,14,19,31 
During the analysis of tumor relapse in this study, 
lymphomas recurred during follow-up in 5 of 7 patients who 
had lymphoma in the conjunctiva, with a high recurrence rate 
of 71.4%. On the other hand, in the 9 patients with tumors 
limited to the orbit, relapse was not detected after treatments. 
Thus, the recurrence rate was significantly different from the 
cases in which the tumor invaded the conjunctiva. A number 
of environmental factors have been implicated in the 
occurrence of non-Hodgkin's lymphoma, including infectious 
agents, chemical exposure, and medical treatment.
32 De Jong 
D et al. reported that the chronic inflammation or chronic 
irritation of antigens lead to a loss of the control of 
proliferation and differentiation in B lymphocytes.
33 Chronic 
ocular irritations from infectious agents including viruses, 
environmental factors, eye drops or preservatives may induce 
MALT lymphoma. Byon et al. reported that lymphoma cells 
remained in the conjunctiva after therapy despite regular 
histological testing and treatment.
34 These remaining cells 
may not have been detected due to the fact that previous 
reports simply reflected the clinical improvement without 
periodic conjunctival histopathologic examination. Conven-
tional therapeutic modalities for malignant lymphoma 
occurring in the conjunctiva may need to be reconsidered. 
Even if specific conjunctival lesions like salmon patch are not 
detected, more careful observation including periodic 
histopathologic examination during follow-up is required.
After treatment of primary malignant lymphomas in the 
orbit, residual tumors were detected in 4 patients on CT. 
After treatment of patients with tumors in the chest from 
non-Hodgkin's lymphoma, residual tumors were detected in 
as often as 40% of patients during the follow-up CT.
35 
Determining complete remission in patients is a remaining 
problem. Surbone et al. have reported that only fibrosis was 
detected in 95% of cases when performing histological 
testing on the residual tumors after treatment for aggressive 
non-Hodgkin's lymphoma.
35 In addition, the study of Coiffier 
et al. showed no difference resulted between CR and CRu 
groups in the recurrence rate, the disease-free survival rate, 
or in the total survival rate.
36 Therefore, the cases without 
any change in the size of lesions for a proper period were 
reclassified as complete remission.
In this study, all of the 17 patients with ocular adnexa 
lymphoma responded well to conventional treatments. 
However, the risk of the relapse was high when it occurred 
in the conjunctiva or simultaneously invaded both eyes. And 
residual tumors may remain after treatment for the some 
patients with the lymphoma in the orbit. Hence, for the Korean  J  Ophthalmol  Vol.20,  No.1,  2006
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treatment of lymphoma, it is important to precisely diagnose 
the location of lesions, histopathological findings and the 
clinical stage. Long-term follow-up observation may also be 
necessary after treatment.
References
1. Dunbar SF, Linggood RM, Doppke KP, et al. Conjunctival 
lymphoma: results and treatment with a single anterior 
election field. A lens sparing approach. Int J Radiant Oncol 
Biol Phys 1990;19:249-57.
2. The Hematolymphoreticular Study Group of the Korean 
Society of Pathologist. REAL classification of malignant 
lymphomas in the republic of Korea. Cancer 1998;98:806- 
12. 
3. Witherspoon AC, Diss TC, Pan L, et al. Primary low-grade 
B-cell lymphoma of the conjunctiva: a mucosa-associated 
lymphoid tissue type lymphoma. Histopathology 1996;28: 
129-34.
4. Shirai K, Okada Y, Saika S, Ohnishi Y. A case of 
mucosaassociated lymphoid tissue (MALT) lymphoma of 
presumed lacrimal gland origin. Ganka Rinsho Iho (Jpn Rev 
Clin Ophthalmol) 1996;90:604-6.
5. Coupland SE, Krause L, Delecuse HJ, et al. Lympho-
proliferative lesions of the ocular adrexa: analysis of 112 
cases.  Ophthalmology 1998;105:1430-41.
6. Harris NL, Jaffe ES, Diebold J, et al. The World Health 
Organization classification of neoplastic disease of the 
haematopoietic and lymphoid tissues: report of the Clinical 
Advisory Committee Meeting, Airlie house, Virginia, 
November 1997, Histopathology 2000;36:69-87.
7. Harris NL, Jaffe ES, Stein H, et al. A revised European- 
American classification of lymphoid neoplasm: a proposal 
from the international lymphoma study group. Blood 
1994;84:1361-92.
8. Ellis JH, Banks PM, Campbell RJ, Liesegang TJ. Lymphoid 
tumors of the ocular adnexa. Clinical correlation with the 
working formulation classification and immunoperoxidase 
staining of paraffin sections. Ophthalmology 1985;92:1311- 
24.
9. White WL, Ferry JA, Harris NL, Grove AS Jr. Ocular 
adrexal lymphoma. A clinicopathologic study with identifi-
cation of lymphomas of mucosa-associated lymphoid tissue 
type.  Ophthalmology 1995;102:1994-2006.
10. Erkal HS, Serin M, Sak SD, Cakmak A. Radiation therapy 
for stage I primary orbital non-Hodgkin's lymphomas. 
Tumori 1997;83:822-5.
11. Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: 
radiotherapy outcome and complications. Radiother Oncol 
2001;59:139-44.
12. Pelloski CE, Wilder RB, Ha CS, et al. Clinical stage 
IEA-IIEA orbital lymphomas: outcomes in the era of 
modern staging and treatment. Radiother Oncol 2001;59: 
149-51.
13. Bolek TW, Moyses HM, Marcus RB Jr, et al. Radiotherapy 
in the management of orbital lymphoma. Int J Radiat Oncol 
Biol Phys 1999;44:31-6.
14. Ohtsuka K, Hashimoto M, Suzuki Y. A review of 244 orbital 
tumors in Japanese patients during a 21-year period: origins 
and locations. Jpn J Ophthalmol 2005;49:49-55.
15. Jenkins C, Rose GE, Bunce C, et al. Histological features 
of adnexal lymphoma (REAL classification) and their 
association with patient morbidity and survival. Br J 
Ophthalmol 2000;84:907-13.
16. Rosenberg SA, Boiron M, DeVita VT Jr, et al. Report of 
the Committee on Hodgkin's Disease Staging Procedure. 
Cancer Res 1071;31:1862-3.
17. Kim YH, Fayos JV. Primary orbital lymphoma: a radio-
therapeutic experience. Int J Radiat Oncol Biol Phys 
1976;1:1099-105.
18. Smitt MC, Donalldson SH. Radiotheraphy is successful 
treatment for orbital lymphoma. Int J Radiat Oncol Biol 
Phys 1995;31;929-34.
19 Esik O, Ikeda H, Mukai K, Kaneko A. A retrospective 
analysis of different modalities for treatment of primary 
orbital non-Hodgjin's lymphoma. Radiother Oncol 1996; 
38:13-8.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an 
international workshop to standardize response criteria for 
non-Hodgkin's lymphomas. NCI Sponsored Working Group. 
J Clin Oncol 1999;17:1244.
21. Nango K, Furumura T, Uyama M. Histopathological 
analysis of 53 cases of orbital tumors. Folia Ophthamol Jpn 
1992;42:1271-8.
22. Hiroshi T, Kazuhito T, Hidetoshi Y. Diagnosis and treatment 
of orbital malignant lymphoma: 14-year review at Yamagata 
university.  Jpn J Ophthalmol 2001;45:305-12.
23. Medeiros LJ, Harris NL. Lymphoid infiltrates of the orbit 
and conjunctiva: a morphologic and immunophenotypic 
study of 99 cases. Am J Surg Pathol 1989;13:459-71.
24. Knowles DM, Jakobiec FA, McNally L, Bruke JS. Lymphoid 
hyperplasia and malignant lymphoma occurring in the 
ocular adnexa (orbit, conjunctiva, and eyelids): a prospec-
tive multiparametric analysis of 108 cases during 1977 to 
1987.  Hum Pathol 1990;21:959-73.
25. Jo YJ, Yim JH, Park KS. MALT (mucosa associated 
lymphoid tissue) type lymphoma of the ocular adnexa. J 
Korean Ophthalmol Soc 2002;43:357-62.
26. Kim SS, Ahn SD, Chang HS, et al. Primary orbital 
lymphoma: A retrospective analysis of result of radiation 
therapy.  Korean Soc Ther Radiol Oncol 2002;20:139-46.
27. Cho EY, Han JJ, Ree HJ, et al. Clinicopathologic Analysis 
of ocular adnexal lymphomas: Extranodal marginal zone 
B-cell lymphoma constitutes the vast majority of ocular 
lymphomas among Koreans and affects younger patients. 
Am J Hematol 2003;73:87-96.
28. Lee JL, Kim MK, Lee KH, et al. Extranodal marginal zone 
B-cell lymphomas of mucosa-associated lymphoid tissue- 
type of the orbit and ocular adnexa. Ann Hematol 2005;84: 
13-8.
29. Lauer SA. Ocular adnexal lymphoid tumors. Curr Opin 
Ophthalmol 2000;11:361-6.
30. Hornblass A, Jakobiek FA, Reifler DM, Mines J. Orbital 
lymphoid tumor located predominantly within extraocular 
muscles.  Ophthalmology 1987;94:688-97.
31. Galieni P, Polito E, Leccisotti A, et al. Localized orbital 
lymphoma.  Haematologica 1997;82:436-9.
32. Hauke RJ, Armitage JO. A new approach to non-Hodgkin's 
lymphoma.  Intern Med 2000;39:197.
33. de Jong D, Aleman BMP, Taal BG, et al. Controversies 
and consensus in the diagnosis, work-up and treatment of 
gastric lymphoma: an international survey. Ann Oncol 
1999;10:275-80.
34. Byon DS, Moon YS, Kim JS, Kwak HJ. Histological 
progress observation of conjunctival MALToma. J Korean 
Ophthalmol Soc 2002;43:443-8.
35. Surbone A, Longo DL, DeVita VT Jr, et al. Residual 
abdominal masses in aggressive non-Hodgkin's lymphoma 
after combination chemotherapy: significance and manage-
ment.  J Clin Oncol 1988;6:1832-7.
36. Coiffier B, Lepage E. Prognosis of aggressive lymphomas: 
a study of five prognostic models with patients included in 
the LNH-84 regimen. Blood 1989;74:558-64.